News

Known for its work in the field of messenger RNA therapeutics, BioNTech is looking for new ways to grow. Earlier this month, the private...

Biologics have been a business boon to contract manufacturers, Catalent included. Large-molecule drugs are such a focus, in fact, that last year Catalent split its...

Neither Pfizer or Novartis are among the handful of companies at the leading edge of NASH drug development, which has yet to advance a...

Alzheimer's drug development is notoriously difficult, exemplified by the fact there are no therapies approved to treat the underlying disease. That's not for a lack...

The move by PhRMA and its members to address calls for more transparency on drugs prices came to a head in October, when the...

Deloitte's annual report on R&D productivity, while limited in scope, is an indicator of the challenges faced by large pharmaceutical firms in bringing new...

The plaques are considered hallmarks of Alzheimer's disease, formed in the brain from sticky clusters of a misfolded protein fragment called beta-amyloid. For the past...

By most measures, Novartis enjoyed a positive start to 2019. Drug sales rose by 5% in dollar terms, lifted by strong performances from the Swiss...

The RDC prosecution could serve as a warning to the drug distribution industry, potentially impacting litigation against the three largest players: McKesson, AmerisourceBergen and...

CAR-T therapies represent a significant clinical advance for patients with certain types of advanced lymphoma. In clinical testing, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)...